Chief Executive Officer, Exploristics
Aiden Flynn is the founder and CEO of Exploristics and has 25 years’ experience as a statistician in drug discovery and clinical development.
With key expertise in emerging approaches to clinical development such as Precision Medicine and biomarker discovery, validation and integration, Aiden has worked closely with regulatory authorities, such as the FDA and EMA, to develop tools and guidelines that support the use of biomarkers in clinical studies. He has over 40 publications in peer reviewed journals and books and is an invited speaker at international conferences. Aiden is also a member of the Precision Medicine Advisory Board at Merck Biopharm and is involved in the Precision Medicine Steering Group, offering strategic advice to the Department of Health